![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Objective
Neuroblastic tumors are the most common solid tumors in children. The aim of this study was to explore the prognostic value of immunostaining for cellular-myelocytomatosis viral oncogene (c-MYC) expression in patients with peripheral neuroblastic tumors (NTs).
Methods
A retrospective study was conducted to compare the expression of c-MYC detected by immunohistochemistry and v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) by fluorescence in situ hybridization among 177 cases of NTs and determine the associations of c-MYC and MYCN with the clinical stages, morphological types, and survival rates of NTs.
Results
The cases positive for c-MYC were mainly the favorable histology type in stage 3 or 4 with a poor NT prognosis, but no morphological changes related to the poor prognosis were observed in their samples under a microscope. The cases with positive c-MYC expression did not overlap those with MYCN amplification.
Conclusion
Positive c-MYC expression portends a poor prognosis in patients with NTs.
Ethics Approval and Consent to Participate
This study was carried out within an appropriate ethical framework. The patients’ parents understood the scientific research uses, and all experimental procedures were approved by the Biomedical Ethics Committee of Chongqing Medical University. This study was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all participants.
Consent for Publication
All patient guardians signed a document of informed consent.
Acknowledgments
We would like to acknowledge the hard and dedicated work of all the staff that implemented the intervention and evaluation components of the study.
Disclosure
The authors declare that they have no competing interests.